Merrill keeps Amgen at neutral

Amgen Inc. was maintained at neutral by Merrill Lynch analyst Eric Ende on expected solid data from the Cera preclinical study indicating novel and unexpected binding properties. Abstracts indicate that Cera has similar efficacy at maintaining hemoglobin levels as Epogen or Aranesp at certain doses. Patent litigation overhang will remain until at least mid-2007, according to the analyst. Shares of the Thousand Oaks, Calif.-based pharmaceutical company were down $1.26, or 1.92%, at $64.35 on volume of 8,313,854 shares versus the three-month running average of 8,870,130 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.